ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Clinical trial NCT06970912 · RECRUITING

Trial details

NCT number: NCT06970912
Sponsor: Peking University People's Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hormone Receptor-Positive Breast Cancer High-risk Breast Cancer Early-Stage Breast Cancer HER2-negative Breast Cancer ctDNA Monitoring Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Start date: 2025-08-01
Primary completion: 2029-12-31
Enrollment: 393

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.